News | July 11, 2014

DC Devices Closes $34 Million in Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure

July 11, 2014 — DC Devices Inc. has closed a $34 million Series D financing round. Accelmed led the round with contributions from existing investors Third Rock Ventures, General Catalyst Partners and Lumira Capital, as well as a new undisclosed strategic investor. Funds will be used to complete clinical evaluation of the world’s first transcatheter device for the treatment of diastolic heart failure (DHF), a $5 billion global market opportunity.

With heart failure representing the single-biggest cause of hospitalizations in many countries, and the largest expense in the U.S. Medicare budget, new therapies that reduce the heart failure hospitalization rate and improve patients’ quality of life are needed.

The company’s proprietary, minimally invasive InterAtrial Shunt Device (IASD) system is the world’s first device intended to treat DHF, also known as heart failure with preserved ejection fraction (HFpEF). By placing a permanent implant in the atrial septum, the IASD System is designed to reduce elevated left atrial pressure and relieve symptoms. The innovative IASD System allows physicians to perform this transcatheter treatment without open-heart surgery and in a controlled fashion, using standard interventional cardiology techniques.

“Patients who suffer from diastolic heart failure have no effective treatment options and have a poor survival rate,” said George Fazio, president and CEO of DC Devices. “With the support of our investors and the guidance of our clinical advisors, we are now one step closer to bringing a potentially transformative new therapy to heart failure patients around the world.”

The DC Devices clinical advisory board is comprised of a group of international, multi-specialty, leading physicians who bring a broad range and depth of expertise to the company. The advisory board, which provides medical and strategic guidance for product development, clinical, and commercialization activities, includes Drs. Martin Leon, Gerd Hasenfu?, Sanjiv Shah, David Kaye, Piotr Ponikowski, Daniel Burkhoff, Ted Feldman, Laura Mauri, Matthew Maurer, John Cleland and Barry Borlaug among others.

For more information: www.dcdevicesinc.com


Related Content

News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Feature | Heart Valve Technology | Kyle Hardner

Primary care providers (PCPs) stand on the front lines of diagnosing clinically significant valvular heart disease (VHD) ...

Home July 01, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Konica Minolta, Inc. has announced that a research group has developed a simple and rapid technique for ...

Home June 29, 2026
Home
News | Heart Valve Technology

June 18, 2026 — Nyra Medical has been selected as the recipient of the 2026 Jon DeHaan Foundation Award for ...

Home June 19, 2026
Home
News | Heart Valve Technology

April 24, 2026 – A novel detection algorithm spotted moderate-to-severe aortic stenosis (AS) with a sensitivity of 90.5% ...

Home April 24, 2026
Home
News | Heart Valve Technology

April 21, 2026 — A new multicenter study published in The Annals of Thoracic Surgery finds that reoperative surgical ...

Home April 22, 2026
Home
News | Heart Valve Technology

Dec. 26, 2025 — Edwards Lifesciences has announced the company’s SAPIEN M3 mitral valve replacement system, a ...

Home December 24, 2025
Home
News | Heart Valve Technology

Nov. 17, 2025 — Royal Philips has introduced DeviceGuide, an AI-powered device tracking* solution that assists ...

Home November 17, 2025
Home
News | Heart Valve Technology | Cedars-Sinai Medical Center

Oct. 28, 2025 — People who underwent a minimally invasive procedure to have their heart’s aortic valve replaced had ...

Home October 29, 2025
Home
News | Heart Valve Technology

Aug. 28, 2025 — Medtronic plc has announced it received U.S. Food and Drug Administration (FDA) approval for the ...

Home August 29, 2025
Home
Subscribe Now